Lupin
Working at Lupin
Company Summary
Overall Rating
17% above
Highly rated for
Skill Development, Company Culture, Work-Life Balance
Work Policy
Top Employees Benefits
About Lupin
Lupin is a global pharmaceutical company offering a wide range of products such as Branded & Generic Formulations, Biotechnology Products, Active Pharmaceutical Ingredients (APIs) and Specialty. Lupin is a significant player in the therapy areas of Gynaecology, Cardiovascular, Diabetology, Asthma, Paediatric, Central Nervous System (CNS), Gastro Intestinal (GI), Anti-Infective (AI) and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Lupin also holds a global leadership position in the Anti-TB and Cephalosporins segments. With a presence in over 100 countries, Lupin offers high-quality yet affordable medicines for some of the most chronic diseases addressing unmet needs in many parts of the world.
Lupin Subsidiaries
Rubamin
Lupin Digital Health
Polynova Industries
Novel Laboratories Inc
AmbitionBox Best Places to Work in India Awards
Pharma Company
Lupin Ratings
Overall Rating
Category Ratings
Skill Development
Company Culture
Work-Life Balance
Work Satisfaction
Salary & Benefits
Job Security
Promotions/Appraisal
Work Policy at Lupin
Lupin Reviews
Top mentions in Lupin Reviews
Compare Lupin with Similar Companies
Change Company | Change Company | Change Company | ||
---|---|---|---|---|
Overall Rating | 4.2/5 based on 5.8k reviews | 4.1/5 based on 5.5k reviews | 4.1/5 based on 6.5k reviews | 5.0/5 based on 1 reviews |
Highly Rated for | Skill development Company culture Work-Life balance | Salary & Benefits Job Security Skill development | Skill development Salary & Benefits Work-Life balance | Skill development Work-Life balance Salary & Benefits |
Critically Rated for | No critically rated category | No critically rated category | No critically rated category | No critically rated category |
Primary Work Policy | Work from office 85% employees reported | Work from office 87% employees reported | Work from office 72% employees reported | - |
Rating by Women Employees | 4.0 Good rated by 337 women | 4.1 Good rated by 404 women | 4.1 Good rated by 626 women | - no rating available |
Rating by Men Employees | 4.2 Good rated by 5.1k men | 4.1 Good rated by 4.8k men | 4.1 Good rated by 5.5k men | - no rating available |
Job Security | 3.7 Good | 3.9 Good | 3.7 Good | 4.0 Good |
Lupin Salaries
Officer
Research Associate
Production Officer
Junior Officer
Medical Representative
Senior Officer
Marketing Executive
Area Sales Manager
Executive Production
Quality Control Officer
Lupin Interview Questions
Interview questions by designation
Top interview questions and answers
Interview Process at Lupin
People are getting interviews through
Lupin Jobs
Lupin News
Stock Market Live: GIFT Nifty Above 24,700; Bharat Forge, HG Infra, Lupin, Paytm Share Prices In Focus
- The GIFT Nifty was trading above 24,700 in early trade Monday.
- Stock prices of Bharat Forge Ltd., H.G. Infra Engineering Ltd., Lupin Ltd., and One 97 Communications Ltd. may react to news flow over the weekend.
- Live updates on the Indian stock market are available.
- Stay updated with stock market news on NDTV Profit.
Stocks To Watch: Paytm, HG Infra, Aurobindo Pharma, RIL, Lupin
- Paytm is selling a 5.4% stake in PayPay Corp for Rs 2,300 crore to SoftBank.
- HG Infra Engineering's subsidiary has won an order worth Rs 862 crore from NHAI.
- Lupin has acquired trademarks of three anti-diabetes medications from Boehringer Ingelheim.
- RIL has acquired a 74% stake in Navi Mumbai IIA for Rs 1,628 crore.
Lupin acquires 3 anti-diabetes trademarks from Boehringer Ingelheim
- Lupin acquires 3 anti-diabetes trademarks from Boehringer Ingelheim.
- Trademark rights for Gibtulio, Gibtulio Met, and Ajaduo will be transferred to Lupin by March next year.
- These drugs belong to a novel class of oral anti-diabetic drugs, indicated to improve glycemic control in adults with type 2 diabetes mellitus.
- The acquisition strengthens Lupin's diabetes portfolio, enabling them to provide effective and affordable treatment options to millions across India.
Cipla To Sun Pharma: Here Are HSBC's Top Pharma Stock Picks
- HSBC has identified its top picks in the Indian pharmaceutical sector, maintaining a buy rating on Cipla Ltd., Sun Pharmaceutical Industries Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., and Aurobindo Pharma Ltd.
- HSBC believes the loss of gRevlimid sales from January 2026 is already priced into the valuations for Cipla and Sun Pharma.
- Stable generic pricing and the execution of key product launches in the US are expected to drive performance in 2025.
- Increasing focus on complex generics and GLP-1 drugs, such as liraglutide, is also seen as crucial for sustaining growth in the US market.
LIC Cuts Stake In Lupin By Nearly Half To 2.54%
- Life Insurance Corporation (LIC) has reduced its shareholding in Lupin Ltd. by nearly half.
- The share sale was conducted between Sept. 30 and Dec. 6, according to an exchange filing.
- In the second quarter of the current financial year, Lupin reported a 13% revenue rise to Rs 5,672.7 crore.
- Shares of Lupin Ltd. closed 1.21% lower at Rs 2,106.65 on Monday.
Girish Verulkar Becomes the Director of HR at Cipla
- Girish Verulkar has been appointed as the Director of Human Resources at Cipla.
- Verulkar has over 25 years of experience in the field and has held key HR positions in companies like Ashoka Buildcon Limited, Crompton Greaves, Andritz Hydro, Lupin Limited, and Sun Pharma.
- He expressed his happiness about this new career milestone through a LinkedIn post.
- Verulkar holds degrees in Personnel Management and Advanced Human Resource Management.
Stocks To Buy: Sun Pharma, Lupin, Glenmark Pharma Among DRChokseys Top Ideas In Pharma Sector
- Sun Pharma, Lupin, and Glenmark Pharma are among the top ideas in the pharma sector according to DRChoksey Research.
- Nifty Pharma is trading at a 1-year forward PE of 31.4 times, slightly above the 1-year average which is reasonable.
- NDTV Profit's special research section offers subscribers an opportunity to expand their understanding of companies, sectors, and the economy.
- Subscribe to NDTV Profit to unlock subscriber-only benefits such as access to stories, research reports, and exclusive content.
Lupin recalls over 6 lakh bottles of hypertension drug in US: USFDA
- Lupin Pharmaceuticals Inc, a subsidiary of Lupin, is recalling over 6 lakh bottles of Ramipril capsules in the US.
- The recall is due to a manufacturing issue related to the active pharmaceutical ingredient sourced from an unapproved vendor.
- The affected lot consists of 2.5 mg, 5 mg, and 10 mg strength tablets manufactured at Lupin's Goa-based facility.
- Dr Reddy's Laboratories is also recalling 3,416 bottles of IBU 600 mg tablets in the US due to failed specifications.
Stocks To Buy: Dr. Reddy's, Lupin Among Axis Securities' Top Ideas From Healthcare Sector
- Axis Securities recommends Dr. Reddy's and Lupin among its top ideas from the healthcare sector.
- Axis Securities sees high operating leverage in hospitals and expects flat sequential growth in the pharmaceutical sector after Q2 results.
- The recommendation to buy these stocks is based on the analysis of the healthcare sector.
- The research reports from top brokerages, asset managers, and research agencies are collected to provide in-depth equity and economy research to subscribers.
Lupin Bets On Respiratory, Injectables To Sustain Growth, Margins In US Market
- Lupin's Q2 net profit rose 74% YoY to Rs 852.6 crore.
- Lupin's US sales dipped sequentially to $220 million in Q2FY25.
- Lupin's Global Executive Director is optimistic about sustaining growth and margins in the US market.
- The company is focusing on respiratory and injectables to sustain growth and margins.
Compare Lupin with
Contribute & help others!
Companies Similar to Lupin
Lupin FAQs
Reviews
Interviews
Salaries
Users/Month